Accelerating CMC Success in Rare Disease Drug Development
New drug approvals in rare diseases are rising, bringing hope to patients. But with accelerated…
Certara2025年2月26日
Leveraging Real-World Evidence (RWE) in Rare Disease Drug Development
The path to regulatory approval and market access for rare disease therapies presents unique challenges.…
Certara2025年2月26日
Bridging Global Health Disparities in Rare Disease Drug Development
Rare diseases know no borders—but access to life-changing treatments remains unequal across the world. In…
Certara2025年2月26日
Advancing Rare Disease Therapies: The Power of Regulatory Expertise
Bringing treatments to patients with rare diseases has long been one of the biggest challenges…
Certara2025年2月26日
How Biosimulation is Transforming Rare Disease Drug Development
Developing therapeutics for rare diseases comes with unique challenges—small patient populations, high variability in treatment…
Certara2025年2月26日
Gene Therapy: A Transformative Shift in Rare Disease Treatment
After decades of promise, gene therapy is finally starting to deliver on its potential—especially for…
Certara2025年2月26日
Navigating Rare Disease Regulations: Challenges, Opportunities, and Innovative Solutions
Bringing life-changing therapies to rare disease patients requires expertise, innovation, and a deep understanding of…
Certara2025年2月26日
Why FDA’s omaveloxolone approval for Friedreich’s ataxia matters
2025年1月10日 Friedreich’s Ataxia (FA) is a rare, genetic, and progressive neurodegenerative disorder. A…
Certara2025年1月10日
